These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 32044043)

  • 21. Insights for the application of TILs and AR in the treatment of TNBC in routine clinical practice.
    Losurdo A; De Sanctis R; Fernandes B; Torrisi R; Masci G; Agostinetto E; Gatzemeier W; Errico V; Testori A; Tinterri C; Roncalli M; Santoro A
    Sci Rep; 2020 Nov; 10(1):20100. PubMed ID: 33208857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
    Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
    Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical Profile of Breast Cancer Patients at a Tertiary Care Hospital in New Delhi, India.
    Doval DC; Sharma A; Sinha R; Kumar K; Dewan AK; Chaturvedi H; Batra U; Talwar V; Gupta SK; Singh S; Bhole V; Mehta A
    Asian Pac J Cancer Prev; 2015; 16(12):4959-64. PubMed ID: 26163622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistological Expression of SOX-10 in Triple-Negative Breast Cancer: A Descriptive Analysis of 113 Samples.
    Kriegsmann K; Flechtenmacher C; Heil J; Kriegsmann J; Mechtersheimer G; Aulmann S; Weichert W; Sinn HP; Kriegsmann M
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32899175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-L1 diagnostics in the neoadjuvant setting: implications of intratumoral heterogeneity of PD-L1 expression in triple negative breast cancer for assessment in small biopsies.
    Stovgaard ES; Bokharaey M; List-Jensen K; Roslind A; Kümler I; Høgdall E; Nielsen D; Balslev E
    Breast Cancer Res Treat; 2020 Jun; 181(3):553-560. PubMed ID: 32358635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
    Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
    Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients.
    Ricciardi GR; Adamo B; Ieni A; Licata L; Cardia R; Ferraro G; Franchina T; Tuccari G; Adamo V
    PLoS One; 2015; 10(6):e0128368. PubMed ID: 26039245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune Profiles of Tumor Microenvironment and Clinical Prognosis among Women with Triple-Negative Breast Cancer.
    Deng L; Lu D; Bai Y; Wang Y; Bu H; Zheng H
    Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):1977-1985. PubMed ID: 31533938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Computer-aided evaluation of the correlation between MRI morphology and immunohistochemical biomarkers or molecular subtypes in breast cancer.
    Jiang S; Hong YJ; Zhang F; Li YK
    Sci Rep; 2017 Oct; 7(1):13818. PubMed ID: 29062076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Folate receptor-α (FOLR1) expression and function in triple negative tumors.
    Necela BM; Crozier JA; Andorfer CA; Lewis-Tuffin L; Kachergus JM; Geiger XJ; Kalari KR; Serie DJ; Sun Z; Moreno-Aspitia A; O'Shannessy DJ; Maltzman JD; McCullough AE; Pockaj BA; Cunliffe HE; Ballman KV; Thompson EA; Perez EA
    PLoS One; 2015; 10(3):e0122209. PubMed ID: 25816016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biological subtype predicts locoregional recurrence after postmastectomy radiotherapy in Chinese breast cancer patients.
    Wang J; Luo J; Jin K; Wang X; Yang Z; Ma J; Mei X; Wang X; Zhou Z; Yu X; Chen X; Guo X
    Cancer Med; 2020 Apr; 9(7):2427-2434. PubMed ID: 32048817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triple negative breast cancer in people of North East India: critical insights gained at a regional cancer centre.
    Sharma M; Sharma JD; Sarma A; Ahmed S; Kataki AC; Saxena R; Sharma D
    Asian Pac J Cancer Prev; 2014; 15(11):4507-11. PubMed ID: 24969877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low expression of tyrosine-protein phosphatase nonreceptor type 12 is associated with lymph node metastasis and poor prognosis in operable triple-negative breast cancer.
    Wu MQ; Hu P; Gao J; Wei WD; Xiao XS; Tang HL; Li X; Ge QD; Jia WH; Liu RB; Xie XM
    Asian Pac J Cancer Prev; 2013; 14(1):287-92. PubMed ID: 23534739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of SIRT1, SIRT3 and SIRT6 Genes for Predicting Survival in Triple-Negative and Hormone Receptor-Positive Subtypes of Breast Cancer.
    Uzelac B; Krivokuca A; Brankovic-Magic M; Magic Z; Susnjar S; Milovanovic Z; Supic G
    Pathol Oncol Res; 2020 Oct; 26(4):2723-2731. PubMed ID: 32681437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A clinicopathological study of triple-negative breast carcinoma in a patient cohort from a tertiary care center in Sri Lanka.
    Wijesinghe HD; Fernando J; Senarath U; Wijesinghe GK; S Lokuhetty MD
    Indian J Pathol Microbiol; 2020; 63(3):388-396. PubMed ID: 32769327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1.
    Chen LL; Zhang ZJ; Yi ZB; Li JJ
    Br J Cancer; 2017 Jun; 117(1):78-88. PubMed ID: 28571042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased number of intratumoral IL-17+ cells, a harbinger of the adverse prognosis of triple-negative breast cancer.
    Qian XL; Xu P; Zhang YQ; Song YM; Li YQ; Li WD; Jiang CY; Shen BB; Zhang XM; Zhang LN; Fu L; Guo XJ
    Breast Cancer Res Treat; 2020 Apr; 180(2):311-319. PubMed ID: 31993861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of immunohistochemically defined molecular subtypes with clinical response to presurgical chemotherapy in patients with advanced breast cancer.
    Khokher S; Qureshi MU; Mahmood S; Nagi AH
    Asian Pac J Cancer Prev; 2013; 14(5):3223-8. PubMed ID: 23803108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
    BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival and local control rates of triple-negative breast cancer patients treated with boost-IOERT during breast-conserving surgery.
    Fastner G; Hauser-Kronberger C; Moder A; Reitsamer R; Zehentmayr F; Kopp P; Fussl C; Fischer T; Deutschmann H; Sedlmayer F
    Strahlenther Onkol; 2016 Jan; 192(1):1-7. PubMed ID: 26403912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.